Neurodegenerative Diseases: Peering in on Protein Interactions

The Scientist is bringing together a panel of experts to share their experience with novel methods for analysis of protein-protein interactions in the brain.

By | September 7, 2016


FREE Webinar

Wednesday, October 26, 2016
2:30 - 4:00 p.m. Eastern Time
View the Video Now

As the population ages, neurodegenerative diseases are becoming increasingly prevalent, bringing with them increased health-care costs, caretaker burden, and an urgent research need. Research into the mechanisms of the most prevalent neurodegenerative diseases, such as Alzheimer’s disease, Parkinson’s disease, and amyotrophic lateral sclerosis, is ongoing, but the molecular underpinnings are still poorly defined. New methods are enabling the direct analysis of protein-protein interactions, and these interactions are painting a clearer picture of the diseases’ mechanisms. The Scientist is bringing together a panel of experts to share their experience bringing these methods to bear on complex diseases. Attendees will have an opportunity to interact with the experts, ask questions, and seek advice on topics that are related to their research.

View the Video Now

Meet the Speakers:

Salvador Sierra-San Nicolás, MD, PhD
Postdoctoral Fellow
Department of Pharmacological Sciences
Icahn School of Medicine at Mount Sinai


Sophia Schedin Weiss, PhD
Associate Professor
Center for Alzheimer Research
Department of Neurobiology, Care Sciences and Society
Karolinska Institutet


Millipore Sigma

Add a Comment

Avatar of: You



Sign In with your LabX Media Group Passport to leave a comment

Not a member? Register Now!

LabX Media Group Passport Logo

Popular Now

  1. Running on Empty
    Features Running on Empty

    Regularly taking breaks from eating—for hours or days—can trigger changes both expected, such as in metabolic dynamics and inflammation, and surprising, as in immune system function and cancer progression.

  2. Authors Peeved by APA’s Article Takedown Pilot
  3. Athletes’ Microbiomes Differ from Nonathletes
  4. Was a Drop in CRISPR Firms’ Stock Warranted?